The ARHGAP5 Knockout Jurkat Polyclonal Cells product consists of a heterogeneous population of Jurkat T lymphocytes subjected to CRISPR/Cas9-mediated disruption of the ARHGAP5 gene locus. This polyclonal knockout cell pool enables loss-of-function studies without the clonal selection bottlenecks inherent to single-cell-derived models, providing a diverse and robust platform for investigating ARHGAP5-dependent biology. The engineered cells are supplied as a mixed population, with gene disruption confirmed at the population level, suitable for immediate use in functional assays.
Jurkat cells are an immortalized human T lymphocyte line originally derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. This extensively characterized cell model recapitulates key aspects of T cell receptor (TCR)-mediated signaling, activation, and leukemogenesis. The Jurkat background is widely employed to dissect signal transduction cascades governing T cell function, immune synapse formation, and oncogenic transformation, making it an ideal host for probing the role of ARHGAP5 in lymphocyte biology.
ARHGAP5 encodes a Rho GTPase-activating protein (RhoGAP) that accelerates GTP hydrolysis on Rho family GTPases, including RhoA, Rac1, and Cdc42, thereby inactivating these molecular switches. The protein functions downstream of integrin ligation and growth factor stimulation, and is regulated by TCR engagement via Src family kinases (e.g., Lck and Fyn) and PI3K. ARHGAP5 interacts with RhoA, Rac1, Cdc42, p120 RasGAP, filamin A, and GRB2, linking it to focal adhesion kinase (FAK) and actin remodeling. Its activity modulates actin polymerization, serum response factor (SRF)-dependent transcription, and cytoskeletal dynamics essential for cell adhesion and migration.
In Jurkat T cells, ARHGAP5-mediated regulation of Rho GTPase activity is critical for TCR-induced actin reorganization at the immune synapse. Loss of ARHGAP5 in this cell model is expected to disturb the spatiotemporal control of actin polymerization, potentially altering immunological synapse stability, cell polarity, and downstream signaling outputs such as cytokine production. This knockout population thus serves as a relevant system to study how aberrant Rho GTPase cycling contributes to T cell dysfunction and leukemia progression, given that Jurkat cells inherently exhibit oncogenic signaling.
Researchers can employ these polyclonal ARHGAP5 knockout Jurkat cells in a range of applications, including examination of TCR-dependent cytoskeletal remodeling via immunofluorescence for F-actin and immune synapse markers, assessment of Rho GTPase activity by western blotting or pull-down assays, and measurement of T cell activation markers by flow cytometry. The model is compatible with functional genomics screens, drug sensitivity profiling for leukemia therapeutics, and migration or invasion assays to evaluate the role of ARHGAP5 in T cell motility. For detailed technical specifications or custom inquiries, please contact Ascent Research.
